Prof Oudard answers "no" to the question "Have additional treatment options had a tangible impact on the first-line treatment of mRCC?" - and tells us why.

Among other things, he argues that the efficacy of targeted agents has reached a plateau; the rapid increase in treatment options complicates the treatment landscape, because clinicians have to become familiar with the characteristics of each agent.

GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.